Testing HIV Patients for other Sexually Transmitted Infections Too Expensive?

Article

Patients with HIV are likely to have other sexually transmitted infections, but routine testing may be too expensive an urban Alabama clinic estimated.

Screening people for sexually transmitted infections in people with HIV is a recommended healthcare practice.

Unfortunately, a study in Alabama concluded, such screening can be prohibitively expensive because insurance reimbursements do not fully cover the costs of laboratory tests.

Reporting at IDWeek 2016 in New Orleans, LA, Kathryn Hudak, BS, and colleagues at the University of Alabama School of Medicine and the university’s Division of Infectious Disease, said follow US Centers for Disease Control and Prevention guidelines would have led to their urban HIV clinic incurring “significant financial losses.”

The current guidelines call for screening all HIV-positive patients for Chlamydia, gonorrhea, syphilis, and trichomonas.

Calculating lab charges vs. reimbursement data for commercial insurance including people who obtained insurance under the Affordable Care Act, Medicaid, and Medicare, the team estimated that insurance did not cover lab costs.

Looking at the cost of testing 3,163 patients (27% Medicare, 13% Medicaid, 26% commercial, and 34% either uninsured or with ACA coverage) they found the cost after reimbursements would be $783,834.76.

“Policy makers should address this lack of compensation to ensure sustainability and compliance with recommended screening,” the team wrote, “Caring for uninsured patients will lead to greater losses.”

Related Coverage:

Boston Study: Men on PrEP Use Condoms Less

Study Recommends Testing People with HIV for STIs

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.